To include your compound in the COVID-19 Resource Center, submit it here.

Astex Therapeutics, SuperGen deal

SuperGen will acquire fellow cancer company Astex in a cash and stock deal. Astex shareholders will receive $25 million in cash, plus shares that will represent 35% of the combined company's outstanding shares after the deal closes. Additionally, Astex shareholders will receive

Read the full 421 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers